Showing 2877 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for…
-
Press release /Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety…
-
Event /
-
Event /